Administrative Core

行政核心

基本信息

  • 批准号:
    10242888
  • 负责人:
  • 金额:
    $ 9.67万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-09-01 至 2023-08-31
  • 项目状态:
    已结题

项目摘要

Project Summary We propose to establish a Consortium to study “Epigenomic Biomarkers of HIV-Associated Cancers in Nigeria.” Our research focus and core services development plan has been prioritized by our Nigerian partners at University of Jos (UniJos), Plateau State, Nigeria located in the center of the country and University of Lagos (UniLag), Lagos State in the densely populated southwest. Our focus on the epigenetics of HIV-associated hepatocellular carcinoma (HCC) and cervical cancer is justified by our extensive collaborative research history in viral diseases including HIV, human papilloma virus, hepatitis B and C viruses. Northwestern University and Mayo Medical School will serve as the high-income American partner institutions which is justified by the long history of research and research training collaboration with the Nigerian institutions coupled with its expertise in global health and ample complementary resources. The specific aims of the Administrative Core (AC) are: 1. establish the administration structure, communication mechanisms, decision making and conflict resolution processes for the U54 Consortium, 2. define the process for establishing and convening the External Advisory Group (EAG) which will include policy makers, health education specialists, institutional and government leaders, key opinion leaders and community advocates from Nigeria, and 3. coordinate administrative efforts between the Biomedical Informatics and Statistics Core (BISC), Career Enhancement Core (CEC), Pathology and Genomics Core (PGC) and Projects 1 (HCC) and 2 (cervical). The AC will be responsible for the overall administration, coordination and management of the Consortium as well as facilitation and coordination of meetings and activities of all cores and projects. The AC will be responsible for evaluating all Consortium activities, including monitoring project progress, monitoring proposed timelines, overseeing quality control procedures, and tracking and reporting progress towards stated research goals. We will develop short, medium and long term metrics for evaluating the quality, quantity, and continuity of the Consortium. An EAG will be formed and its membership will include: policy makers, health education specialists, institutional and government leaders, key opinion leaders and community advocates. The overall goal of the AC will be to support and facilitate research proposed in Projects 1 (HCC) and 2 (cervical), provide administrative logistics for training activities under the CEC, and manage research services provided by the BISC and PGC.
项目摘要 我们建议成立一个联盟来研究“尼日利亚艾滋病毒相关癌症的表观基因组生物标记物”。 我们的研究重点和核心服务发展计划已被我们的尼日利亚合作伙伴优先考虑, 乔斯大学(UniJos),位于尼日利亚中部的高原州立大学和拉各斯大学 位于人口稠密的西南部的拉各斯州(UNILAG)。我们对HIV相关表观遗传学的关注 我们广泛的合作研究历史证明了肝细胞癌和宫颈癌是合理的 在包括艾滋病毒、人乳头瘤病毒、乙型和丙型肝炎病毒在内的病毒性疾病中。西北大学和 梅奥医学院将作为高收入的美国合作机构,这从长远来看是合理的 与尼日利亚机构的研究和研究培训合作的历史,以及它在 全球卫生和充足的补充资源。行政核心(AC)的具体目标是:1. 建立管理结构、沟通机制、决策和冲突解决机制 U54联合体的流程,2.确定建立和召开外部咨询的流程 EAG小组,将包括政策制定者、健康教育专家、机构和政府领导人, 来自尼日利亚的主要意见领袖和社区倡导者,以及3.协调行政工作 生物医学信息学和统计核心(BISC)、职业提升核心(CEC)、病理学和 基因组学核心(PGC)和项目1(肝癌)和项目2(宫颈)。AC将负责整个 联合体的行政、协调和管理,以及促进和协调 所有核心和项目的会议和活动。AC将负责评估所有联合体 活动,包括监测项目进度、监测拟议时间表、监督质量控制 程序,以及跟踪和报告实现既定研究目标的进展情况。我们将发展短、中 以及用于评估联合体的质量、数量和连续性的长期指标。安EAG将成为 已成立,成员包括:政策制定者、健康教育专家、机构和政府 领袖、主要意见领袖和社区倡导者。咨询委员会的总体目标将是支持和 促进项目1(CC)和项目2(CERACH)中提出的研究,为培训提供行政后勤 负责CEC下的活动,并管理BISC和PGC提供的研究服务。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Lifang Hou其他文献

Lifang Hou的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Lifang Hou', 18)}}的其他基金

Epigenetic study of oral HPV infection-associated oral cancer in people living with HIV in Nigeria
尼日利亚 HIV 感染者口腔 HPV 感染相关口腔癌的表观遗传学研究
  • 批准号:
    10530153
  • 财政年份:
    2022
  • 资助金额:
    $ 9.67万
  • 项目类别:
Epigenomic landscape of individual- and neighborhood-level social disadvantages and cardiovascular health disparity
个人和社区层面的社会劣势和心血管健康差异的表观基因组景观
  • 批准号:
    10701077
  • 财政年份:
    2022
  • 资助金额:
    $ 9.67万
  • 项目类别:
Epigenomic landscape of individual- and neighborhood-level social disadvantages and cardiovascular health disparity
个人和社区层面的社会劣势和心血管健康差异的表观基因组景观
  • 批准号:
    10531486
  • 财政年份:
    2022
  • 资助金额:
    $ 9.67万
  • 项目类别:
Epigenetic biomarkers of Cervical HPV in women with oral and oropharyngeal HPV, precancer and cancer
患有口腔和口咽 HPV、癌前病变和癌症的女性中宫颈 HPV 的表观遗传生物标志物
  • 批准号:
    10841283
  • 财政年份:
    2022
  • 资助金额:
    $ 9.67万
  • 项目类别:
Epigenetic study of oral HPV infection-associated oral cancer in people living with HIV in Nigeria
尼日利亚 HIV 感染者口腔 HPV 感染相关口腔癌的表观遗传学研究
  • 批准号:
    10705727
  • 财政年份:
    2022
  • 资助金额:
    $ 9.67万
  • 项目类别:
Infection-Associated Cancer Research Training Program in Mali
马里感染相关癌症研究培训计划
  • 批准号:
    10440364
  • 财政年份:
    2021
  • 资助金额:
    $ 9.67万
  • 项目类别:
Infection-Associated Cancer Research Training Program in Mali
马里感染相关癌症研究培训计划
  • 批准号:
    10645169
  • 财政年份:
    2021
  • 资助金额:
    $ 9.67万
  • 项目类别:
Infection-Associated Cancer Research Training Program in Mali
马里感染相关癌症研究培训计划
  • 批准号:
    10223788
  • 财政年份:
    2021
  • 资助金额:
    $ 9.67万
  • 项目类别:
High Dimensional Mediation Analysis for DNA Methylation Markers Mediating Cardiovascular Health Metrics and Cardiovascular Diseases
DNA 甲基化标记介导心血管健康指标和心血管疾病的高维中介分析
  • 批准号:
    9918838
  • 财政年份:
    2019
  • 资助金额:
    $ 9.67万
  • 项目类别:
Epigenomic Biomarkers of HIV-Associated Cancers in Nigeria
尼日利亚艾滋病毒相关癌症的表观基因组生物标志物
  • 批准号:
    10242887
  • 财政年份:
    2017
  • 资助金额:
    $ 9.67万
  • 项目类别:

相似海外基金

RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    10219039
  • 财政年份:
    2020
  • 资助金额:
    $ 9.67万
  • 项目类别:
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    9981476
  • 财政年份:
    2019
  • 资助金额:
    $ 9.67万
  • 项目类别:
IGF::OT::IGF RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
IGF::OT::IGF 针对获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    9364184
  • 财政年份:
    2016
  • 资助金额:
    $ 9.67万
  • 项目类别:
Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) in Saskatchewan- Where are we now and what does the future hold?
萨斯喀彻温省的人类免疫缺陷病毒(HIV)和获得性免疫缺陷综合症(艾滋病)——我们现在在哪里以及未来会怎样?
  • 批准号:
    236932
  • 财政年份:
    2011
  • 资助金额:
    $ 9.67万
  • 项目类别:
    Miscellaneous Programs
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
  • 批准号:
    3554155
  • 财政年份:
    1991
  • 资助金额:
    $ 9.67万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6766860
  • 财政年份:
    1991
  • 资助金额:
    $ 9.67万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
  • 批准号:
    3554156
  • 财政年份:
    1991
  • 资助金额:
    $ 9.67万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6256640
  • 财政年份:
    1991
  • 资助金额:
    $ 9.67万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW
获得性免疫缺陷综合症研究综述
  • 批准号:
    2063342
  • 财政年份:
    1991
  • 资助金额:
    $ 9.67万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6091256
  • 财政年份:
    1991
  • 资助金额:
    $ 9.67万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了